6929 (6929) Fair Value & Analysis

Healthcare · Market cap HK$3.2B

6 6929 6929 · HK

PriceHK$3.74

Fair ValueHK$0.8500

Upside-77.3%

Quality57/100

Watch 6929 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$0.5600 – HK$1.24

Fair value as of: Jul 2, 2026

From 25 valuation models · updated today

Share price −8.3% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$3.34 – HK$5.14 · fair‑value band HK$0.5600 – HK$1.24 · the HK$3.74 price screens above the HK$0.8500 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

6929 (6929) currently trades at HK$3.74, while our model-based Fair Value estimate is HK$0.8500 — implying the stock looks roughly 77.3% overvalued today. We read business quality at 57/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 6929 generated revenue of HK$180M at a net margin of 23.2%. Revenue grew 13.8% year over year. It earns a return on equity of 10.4%. The balance sheet holds a net cash position of HK$215M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$180M

Revenue growth (YoY) +13.8%

Net margin 23.2%

Return on equity 10.4%

Free cash flow HK$1.1M FY2025

P/E ratio 9.6

More key figures

Operating margin 24.4%

EPS (TTM) HK$0.0200

Dividend yield 0.4%

EPS growth (YoY) +5.9%

Net cash HK$215M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

6929 reported revenue of HK$180M in FY2025 versus HK$116M in FY2021, a compound +11.6%/yr. Reported net income was HK$41.9M in FY2025.

Revenue +11.6%/yr

FY21 HK$116M

FY22 HK$137M

FY23 HK$154M

FY24 HK$164M

FY25 HK$180M

Net income

FY21 −HK$4.4M

FY22 HK$18.5M

FY23 HK$45.1M

FY24 HK$39.7M

FY25 HK$41.9M

Is 6929 fairly valued? → Check now

Similar stocks

6 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Intuitive Surgical, Inc ISRG	$422.06	$165.35	-61%
EssilorLuxottica Société anonyme ESLOF	$192.00	$126.51	-34%
HOYA Corporation HOCPY	$178.46	$103.27	-42%
Medline Inc MDLN	$36.54	$30.66	-16%
Becton, Dickinson and Company BDX	$140.71	$104.17	-26%
Alcon Inc ALC	$65.18	$44.21	-32%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 6929 (6929) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.8500 versus a price of HK$3.74 — about −77% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 6929?

Our model-based fair value for 6929 is HK$0.8500 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$3.74.

What is the quality score of 6929?

6929 has a Quality Score of 57/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 6929 (6929)?

6929 reported trailing-twelve-month revenue of about HK$180M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 6929?

The net profit margin of 6929 is about 23.2%, meaning it keeps roughly 23.2% of revenue as net income. Based on the latest reported figures.

Does 6929 pay a dividend?

6929 currently shows a dividend yield of about 0.38% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.